211 related articles for article (PubMed ID: 37999621)
41. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.
Yang YM; Choi EJ
Ther Clin Risk Manag; 2017; 13():477-497. PubMed ID: 28442915
[TBL] [Abstract][Full Text] [Related]
42. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
43. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan.
Mushtaq S; Akhter TS; Khan A; Sohail A; Khan A; Manzoor S
Front Pharmacol; 2020; 11():550205. PubMed ID: 32982753
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports.
Higley C; Hsu CC; Smith C; Nadella S; Lalos AT
World J Hepatol; 2020 Dec; 12(12):1341-1348. PubMed ID: 33442459
[TBL] [Abstract][Full Text] [Related]
46. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
47. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.
Gao LH; Nie QH; Zhao XT
Int J Gen Med; 2021; 14():289-301. PubMed ID: 33536776
[TBL] [Abstract][Full Text] [Related]
48. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.
Scotto R; Buonomo AR; Moriello NS; Maraolo AE; Zappulo E; Pinchera B; Gentile I; Borgia G
Rev Recent Clin Trials; 2019; 14(3):173-182. PubMed ID: 30848211
[TBL] [Abstract][Full Text] [Related]
49. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation.
Cardona-Gonzalez MG; Goldman JD; Narayan L; Brainard DM; Kowdley KV
Hepatol Commun; 2018 Dec; 2(12):1446-1450. PubMed ID: 30556034
[TBL] [Abstract][Full Text] [Related]
50. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
51. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
52. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Chen P; Jin M; Cao Y; Li H
Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
[TBL] [Abstract][Full Text] [Related]
54. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
56. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
57. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
De A; Roy A; Verma N; Mishra S; Premkumar M; Taneja S; Singh V; Duseja A
Nephrology (Carlton); 2022 Jan; 27(1):82-89. PubMed ID: 34453374
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
[TBL] [Abstract][Full Text] [Related]
59. Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Pearlman BL; Hinds AE
Aliment Pharmacol Ther; 2018 Nov; 48(9):914-923. PubMed ID: 30288771
[TBL] [Abstract][Full Text] [Related]
60. Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Struble K; Chan-Tack K; Qi K; Naeger LK; Birnkrant D
Hepatology; 2018 Feb; 67(2):482-491. PubMed ID: 29059462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
